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Abstract
Background: Endothelium-derived nitric oxide plays an important role for the bone marrow microenvironment. Since
several important effects of nitric oxide are mediated by cGMP-dependent pathways, we investigated the role of the cGMP
downstream effector cGMP-dependent protein kinase I (cGKI) on postnatal neovascularization.
Methodology/Principal Findings: In a disc neovascularization model, cGKI
2/2 mice showed an impaired neovascularization
as compared to their wild-type (WT) littermates. Infusion of WT, but not cGKI
2/2 bone marrow progenitors rescued the
impaired ingrowth of new vessels in cGKI-deficient mice. Bone marrow progenitors from cGKI
2/2 mice showed reduced
proliferation and survival rates. In addition, we used cGKIa leucine zipper mutant (LZM) mice as model for cGKI deficiency.
LZM mice harbor a mutation in the cGKIa leucine zipper that prevents interaction with downstream signaling molecules.
Consistently, LZM mice exhibited reduced numbers of vasculogenic progenitors and impaired neovascularization following
hindlimb ischemia compared to WT mice.
Conclusions/Significance: Our findings demonstrate that the cGMP-cGKI pathway is critical for postnatal neovascularization
and establish a new role for cGKI in vasculogenesis, which is mediated by bone marrow-derived progenitors.
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Introduction
Mice deficient for endothelial nitric oxide synthase (eNOS)
show a defective neovascularization [1], which is, at least in part,
related to an impaired mobilization of vasculogenic progenitor
cells [2]. In contrast to angiogenesis, which results from the
migration and proliferation of pre-existing mature endothelial
cells [3], vasculogenesis is based on the recruitment and
incorporation of bone marrow-derived progenitors to sites of
neovascularization [4–6]. Endothelium-derived nitric oxide (NO)
plays an essential role in the bone marrow microenvironment
and is essential for the mobilization of progenitor cells [2,7–10].
However, NO bioavailability is typically reduced in patients with
diabetes, coronary artery disease, and ischemic cardiomyopathy
(ICMP) [11–13]. Consequently, bone marrow progenitors from
patients with diabetes or ICMP show a reduced neovasculariza-
tion capacity, which is a drawback for their use in cell therapy
[14]. The impaired functional activity of bone marrow cells from
patients could be partially restored after pharmacological
enhancement of eNOS expression or nitric oxide donors, which
highlights the important role of endothelium-derived NO for
neovascularization [15,16]. One important downstream signal-
ing pathway of endothelium-derived NO is mediated by cyclic
guanosine monophosphate (cGMP) as second messenger.
Elevated levels of intracellular cGMP modulate phosphodiester-
ases, open cation channels, and activate cGMP-dependent
protein kinases (cGK; also called protein kinase G; PKG) [17].
The cGKs belong to the family of serine/threonine kinases
[18,19]. Mammals have two cGK genes, which encode cGKI
and cGKII. The NH2-terminus of cGKI is encoded by two
alternative exons producing the isoforms cGKIa and cGKIb.
The cGKI isoforms are soluble enzymes and interact with
several proteins through their NH2-termini containing leucine/
isoleucine zippers (LZ). Here, we investigated the role of the NO
downstream signaling protein cGKI for postnatal neovascular-
ization in two different models for cGKI deficiency, cGKI
2/2
mice and mice with a cGKI mutation that affects downstream
signaling (LZM mice).
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To study the role of cGKI for neovascularization in vivo,w e
subcutaneously implanted discs into the flanks of cGKI
2/2 mice
and their wild-type (WT) littermates. The implantation of discs
stimulates neovascularization due to sterile inflammation. After
two weeks, animals were sacrificed, and, prior to explantation of
the disks, fluorescent microspheres were infused into the
circulation to demonstrate the perfusion of the vessels growing
from the rim to the center of the disc. Gross examination of the
explanted disk already revealed a clear reduction in the
vascularized area for cGKI
2/2 mice compared to WT (Fig. 1A).
In addition, formation of neovessels was demonstrated by staining
for the endothelial marker CD31 (Fig. 1B). Quantitative analysis
demonstrated that neovascularization of the discs in cGKI
2/2
mice was strongly reduced compared with their WT littermates
(Fig. 1C).
Disc neovascularization depends on both angiogenesis and
vasculogenesis. Therefore, sprouting of pre-existing endothelial
cells, which have been reported to express cGKI [20], is likely to
be involved in disc neovascularization. To evaluate the role of
vasculogenesis, i.e. the involvement of bone marrow-derived
progenitor cells, in the impaired neovascularization of sponges
implanted into cGKI
2/2 mice, we examined the capacity of bone
marrow-derived progenitors to restore neovascularization in the
disc model after their systemic infusion. We injected 10
6 donor
cGKI
2/2 or WT bone marrow mononuclear cells (BMC) into
cGKI
2/2 recipient mice (Fig. 2A). Intravenous cell therapy with
WT but not cGKI-deficient donor BMC clearly rescued the
impaired neovascularization of cGKI
2/2 recipient mice (p,0.01;
Fig. 2A). Consistently, neovascularization in WT recipient mice
could be strongly enhanced by injection of WT BMC, whereas
injection of cGKI
2/2 BMC had only a weak effect (Fig. 2B).
These data imply that cGKI in bone marrow progenitor cells plays
an important role to restore postnatal neovascularization in an
inflammation-induced neovascularization model in cGKI
2/2
mice.
To provide further insights into the regulation of vasculogenesis
through cGMP-dependent pathways, we examined the role of
cGKI on the functional capacity of bone marrow-derived
progenitor cells. First, we demonstrated that cGKI is expressed
in freshly isolated CD45
+ hematopoietic bone marrow cells, freshly
isolated total bone marrow, as well as cultured bone marrow
stromal cells (Fig. 3A+B). The most prominent expression of
cGKI was found in cultured bone marrow stromal cells, most
likely due the relative enrichment of endothelial cells and
fibroblasts in cultured bone marrow stromal cells. To assess the
functional capacity of bone marrow-derived progenitor cells, we
measured proliferation and apoptosis rates in Lin
2sca-1
+ bone
marrow progenitor cells (Fig. 4A–C). BrdU incorporation as a
marker of cell proliferation was assessed by flow cytometry and
demonstrated a strong reduction in Lin
2sca-1
+ bone marrow
progenitor cells from cGKI
2/2 mice (Fig. 4A+B). Simultaneous-
ly, the number of apoptotic Lin
2sca-1
+ bone marrow progenitor
cells was increased in cGKI
2/2 mice as assessed by annexin V
binding (Fig. 4C). These results suggest that cGKI promotes
proliferation and survival of bone marrow-derived progenitor cells,
which contributes to neovascularization.
The cGKI
2/2 mice used for the above experiments show
multiple phenotypes and a reduced life expectancy, which
complicates long-term experiments with adult mice and excludes
assessment of neovascularization in ischemia models [18,19]. To
validate the results obtained in juvenile cGKI
2/2 mice in an adult
model of cGKI deficiency, we also examined the neovasculariza-
tion capacity of so-called LZM mice [21]. LZM mice carry a
mutation in the NH2-terminal protein interaction domain of
cGKIa that results in disruption of cGKIa interactions with key
downstream signaling molecules like myosin phosphatase and Rho
kinase, but does not reduce the life span of the mutant mice. In
line with the results from juvenile cGKI
2/2 mice, we observed in
LZM mice a reduced neovascularization capacity, measured as
relative Laser Doppler-derived blood flow, in a model of hindlimb
ischemia (Fig. 5A). In addition, the vessel density assessed as
number of CD31
+ capillaries was lower in LZM mice (Fig. 5B).
Consistently, the number of spleen-derived vasculogenic progen-
Figure 1. Growth of vessels in the neovascularization disc
model of cGKI
2/2 and wild-type (WT) mice. (A) Discs after
explantation from cGKI
2/2 and WT mice. (B) Vessels growing from the
rim of the disc into the center in cGKI
2/2 and WT mice identified by
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mice (Fig. 6A+B). The reduced number and colony formation of
vasculogenic progenitors might be involved in the impaired
neovascularization of LZM mice. These results suggest that
cGKIa in vasculogenic progenitors is also involved in the
neovascularization response following ischemia.
Discussion
The major finding of our investigation is a novel role for cGKI
in the functionality of bone marrow-derived progenitors. Signaling
through cGKI significantly contributed to postnatal neovascular-
ization via stimulation of vasculogenic processes both in the setting
of inflammation and following tissue ischemia. Our data implicate
that the cGMP-cGKI pathway plays a pivotal stimulatory role for
neovascularization, which is at least in part mediated through
bone marrow progenitors. cGKI
2/2 mice exhibit a markedly
reduced life span with defects in the relaxation of vascular and
visceral smooth muscle cells, disturbed platelets and red blood
cells, which limits the availability of adult mice [22–25].
Therefore, we further validated our findings using mice with a
mutation in the NH2-terminal protein interaction domain of
cGKIa, the so-called leucine zipper mutant (LZM) mice. This
mutation selectively inhibits downstream signaling of the cGKIa
isoform while leaving the enzyme intact. LZM mice exhibit a
vascular phenotype with increased blood pressure, but reach
adulthood without limitations in their life span [21]. Consistently,
LZM mice exhibited reduced numbers of vasculogenic progenitors
and impaired neovascularization following hindlimb ischemia
compared to WT mice.
Several previous studies have analyzed the importance of cGMP
signaling for neovascularization, particularly for angiogenesis, i.e.
the generation of new vessels through local expansion of mature
endothelial cells. For instance, systemic cGMP enhancement
augmented angiogenesis in ischemic rat brains [26]. Recently,
sildenafil, a phosphodiesterase-5 inhibitor, which inhibits cGMP
degradation, has been reported to enhance angiogenesis [27].
Moreover, in a mouse model of hindlimb ischemia, sildenafil
promoted recovery of vascular perfusion [28]. Based on the use of
pharmacological tools it appeared that neovessel growth in this
experimental set up was stimulated by a cGMP-cGK pathway that
Figure 2. Disc neovascularization following cell therapy. (A)
Vascularized area after intravenous injection of cGKI
2/2 or WT bone
marrow cells (BMC) into cGKI
2/2 recipients (n$7). (B) Vascularized area
after intravenous injection of cGKI
2/2 or WT bone marrow cells (BMC)
into WT recipients (n$6).
doi:10.1371/journal.pone.0004879.g002
Figure 3. Expression of cGKI in the bone marrow. (A)
Representative western blot of cultured bone marrow stromal cells,
freshly isolated total bone marrow cells, and freshly isolated CD45
+
bone marrow leukocytes using an antibody against cGKI (cGKIcom:
detecting cGKIa and cGKIb). ERK1/2 was used as loading control. (B)
Quantification of the ratio cGKIcom : ERK1 protein expression in
cultured stromal cells, total bone marrow, and CD45
+ bone marrow in
129/Sv WT mice (n=3 / group, p=n.s.).
doi:10.1371/journal.pone.0004879.g003
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previous and our present experiments, a study by Yamahara et al.
demonstrated the significance of the the natriuretic peptide-
cGMP-cGKI pathway for angiogenesis [29]. However, the
involvement of cGMP-cGKI signaling in vasculogenesis, i.e. the
contribution of bone marrow-derived progenitor cells to postnatal
neovascularization, had not been investigated to date. Our results
provide evidence that the reduced neovascularization in cGKI
2/2
Figure 4. Functional capacity of BMC from cGKI
2/2 and WT mice. (A) Representative FACS analysis of Lin
2 BMC after pulsing with BrdU for
1 h and staining with BrdU-FITC and sca-1-PE. (B) Proliferation (BrdU
+) of sca-1
+Lin
2 bone marrow progenitor cells from cGKI
2/2 and WT mice (gated
on lymphocyte-monocyte fraction; n=4). (C) Apoptosis (annexinV
+) of sca-1
+Lin
2 bone marrow progenitor cells from cGKI
2/2 and WT mice (gated
on lymphocyte-monocyte fraction; n=3).
doi:10.1371/journal.pone.0004879.g004
Figure 5. Neovascularization capacity in an unilateral hindlimb ischemia model using LZM and WT mice. (A) Perfusion is measured as
relative Laser Doppler-derived blood flow (n$5). (B) Number of CD31
+ capillaries / mm
2 in ischemic hindlimbs of LZM versus WT littermates mice
(n=12–18 sections from 4–6 mice / group).
doi:10.1371/journal.pone.0004879.g005
cGKI for Neovascularization
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bone marrow-derived progenitors as evidenced by their dimin-
ished proliferation and survival, translating into reduced disc
neovascularization in vivo. The first description that cGMP
stimulation could trigger proliferation of hematopoietic stem cells
was provided by Oshita et al. back in 1977 [30]. It is now
becoming apparent that the cGMP-cGKI signaling pathway has
anti-apoptotic/pro-survival effects in diverse cell types [25,31–34].
About 50% of the cGKI
2/2 mice die before the age of 5 to 6
weeks [18] representing an important drawback of this model.
Therefore, we further corroborated our experimental findings
derived from cGKI
2/2 mice using LZM mice. The apparent
spontaneous phenotype of LZM mice is hypertension and vascular
contractile dysfunction in both large and resistance arteries, but
otherwise these mice appear to develop and age normally. More
than ten downstream in vivo target substrates for cGKI have been
found to date [19]. Currently, however, we have not yet identified
the downstream target molecules, which might be affected by the
disturbed leucine zipper interactions in bone marrow-derived
progenitors.
In vascular smooth muscle cells, cGKI binds to myosin light
chain phosphatase (MLCP), which mediates relaxation through a
leucine zipper domain-mediated interaction [35]. LZM knockin
mice harbor a mutation that disrupts the leucine zipper domain
required for cGKIa-mediated regulation of MLCP-induced
relaxation [21]. Of note, the level of the mutant cGKIa protein
in the vascular wall is comparable to the cGKIa protein level
found in WT mice, and mutant cGKIa protein remains responsive
to cGMP. Thus, key feature of the LZM mouse model is
disruption of interactions between cGKIa and its targets, despite
preserved kinase activity.
Collectively, our data highlight the in vivo importance of the
cGMP-cGKI pathway for postnatal neovascularization and
particularly emphasize the role of the cGKIa isoform in
vasculogenesis. Interestingly, a very recent study demonstrated
the potential of the cGMP-elevating drug sildenafil to increase the
number of circulating vasculogenic progenitor cells in patients
with pulmonary arterial hypertension [36]. Further studies using
pharmacological cGMP elevation for the pre-treatment of bone
marrow-derived progenitors will give more insights into the
therapeutic use of modulating the cGMP-cGKI pathway for
cardiovascular cell therapy approaches.
Materials and Methods
Animals
The generation of a cGKI null allele (also termed L- allele) by
Cre-mediated excision of the loxP-flanked exon 10 of the cGKI
gene in germ cells has been described previously [37]. Juvenile (3–
5 weeks old) male and female cGKI
2/2 mice on a 129/Sv genetic
background and their wild-type (WT) littermates were used for
experiments. Mice with a selective mutation in the NH2-terminal
protein interaction domain of cGKIa (LZM mice) have been used
at adult age (males, C57BL/6 genetic background, crossed .10
generations, 8–10 weeks old) [21]. LZM mice harbor a discrete
mutation in cGKIa that disrupts the leucine zipper (LZ) domain
that mediates the interaction of cGKIa with downstream target
proteins. In LZM mice the initial four leucine/isoleucine codons in
exon1a of the endogenous cGKIa gene were replaced by alanines.
For all invasive procedures, mice were anesthetized with
ketamine (100 mg/kg). For induction of hindlimb ischemia,
anaesthesia was performed using medetomidine (Domitor
TM;
Pfizer, Karlsruhe, Germany; 0.1 mg/kg). For post-operative
analgesia carprofen (Rimadyl
TM; Pfizer; 5 mg/kg) was adminis-
tered. All animal protocols were approved by the Institutional
Animal Care and Use Committee (Regierungspra ¨sidium Darm-
stadt, Germany).
BrdU proliferation assay
Total bone marrow cells were obtained by flushing femur and
tibia bones with PBS using 27-gauge needles. Then, cells (10
6 / ml)
were resuspended in RPMI 1640 medium+10% fetal calf serum
(both from Invitrogen, Karlsruhe, Germany), and pulsed with
10 mM BrdU (BrdU flow kit, BD biosciences (BD), Heidelberg,
Germany) for one hour. Staining of surface antigens with a
cocktail of biotinylated antibodies against lineage markers (lineage
marker panel: anti-CD3, anti-B220, anti-CD11b, anti-Gr, anti-
TER119) was performed for 20 min on ice. This step was followed
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another 20 min on ice. Cells were fixed and permeabilized with
Cytofix / Cytoperm buffer according to the manufacturer’s
instructions (BrdU flow kit) and treated with DNase prior to
intracellular staining with FITC-labeled BrdU for 20 min at room
temperature. Stained cells were then analyzed by flow cytometry
using a FACS Calibur (BD) using CellQuest software. Specific cell
fluorescence intensity was calculated by subtracting the signal
obtained with isotype-matched control antibodies (BD).
Apoptosis assay
Total bone marrow cells were cultured for 24 h in ex-vivo 10
medium+100 ng/ml murine SCF (Peprotech, Rocky Hill, NJ).
Then, bone marrow cells were stained with the biotinylated
lineage marker panel (BD) for 20 min on ice, followed by
streptavidin-PE (BD) together with sca-1-FITC and annexinV-
APC (both BD) for another 20 min at room temperature using
annexin binding buffer (BD). Cells were then immediately
analyzed by flow cytometry using a FACS Calibur.
Vasculogenic progenitor assay
Spleens were aseptically removed, homogenized, and laid over
Ficoll solution (Biocoll, Biochrom AG, Berlin, Germany). Mononu-
clear cells were obtained from the Ficoll’s interphases and washed
with PBS. Then, 4610
6 cells per well were seeded on fibronectin-
precoated 24-well plates (10 mg/ml fibronectin in PBS for 1 h at
room temperature; Sigma-Aldrich, Taufkirchen, Germany) and
cultured in 500 mlE B Mm e d i u m +20% FCS+supplements (Cam-
brex Bio Science, Verviers, Belgium) at 37uC. After four days of
culture, vasculogenic progenitors were assayed by co-staining with
1,19–dioctadecyl–3,3,39,39–tetramethylindocarbocyanine-labeled ace-
tylated low-density lipoprotein (DiLDL; CellSystems, St. Katharinen,
Germany) and FITC-conjugated lectin (Sigma-Aldrich) [38].
To obtain colonies with vasculogenic activity, we used a
modified version of the protocol of Ingram et al. [39] using
fibronectin and supplemented EBM medium scoring clusters of
cells after 7 days.
Western blot analysis
Total bone marrow cells, CD45
+ bone marrow leukocytes, and
cultured bone marrow stromal cells were used for Western blot
analysis. CD45
+ cells were isolated by immunomagnetic selection
using magnetically labeled anti-CD45 microbeads and magnetic
cell sorting (Miltenyi Biotec, Bergisch Gladbach, Germany). To
obtain bone marrow stromal cells, total bone marrow cells were
cultured in RPMI 1640 medium+10% fetal calf serum (both from
Invitrogen) for one week. Cells were fed with fresh medium every
other day and non-adherent cells were discarded. After trypsin-
ization of the adherent stromal cells, the pelleted cells were
resuspended in lyzing buffer. Finally, proteins were separated on a
SDS gel, transferred to a PVDF membrane and stained with a
polyclonal rabbit antiserum to cGKI [40]. ERK1/2 (p44/p42
MAPK) antibodies were used as a loading control (Cell Signaling
Technology, Danvers, MA).
Disc neovascularization model
A disc of polyvinyl alcohol sponge (Rippey Corp., El Dorado
Hills, California), covered with nitrocellulose cell-impermeable
filters (Millipore Corp., Burlington, Massachusetts), allows vessels
to grow only through the rim of the disc [41,42]. The discs were
subcutaneously implanted in the back of 3–5 weeks old cGKI
2/2
mice or their WT littermates. For cell therapy, bone marrow cells
were harvested from donor cGKI
2/2 or WT mice by aseptically
flushing femurs and tibias with PBS. Bone marrow mononuclear
cells (BMC) were isolated by density-gradient centrifugation with
Biocoll separating solution (density 1.077; Biochrom AG). Twenty-
four hours after implantation of sponges, we intravenously injected
10
6 BMC from either cGKI
2/2 or WT BMC . Two weeks later,
space-filling fluorescent microspheres (0.2 mm; Molecular Probes
Inc., Eugene, OR) were systemically injected into the left ventricle
to identify functionally connected microvessels in the implaned
disks [43]. The area of the disc invested by fibrovascular ingrowth
was assessed using a Axiovert 40 fluorescence microscope (Zeiss,
Oberkochen, Germany). Alternatively, outgrowth of vessels was
examined by CD31 staining (CD31-FITC; BD biosciences,
Heidelberg, Germany) for endothelial cells.
Hind limb ischemia model
To induce unilateral hind limb ischemia, the proximal portion of
the right femoral artery including the superficial and the deep
branch were occluded using an electrical coagulator. The overlying
skin was closed using surgical staples. Limb perfusion was assessed
with a laser Doppler blood flow imager (Laser Doppler Perfusion
Imager System, moorLDI
TM-Mark 2, Moor Instruments, Wilming-
ton, Delaware) after one week. Before initiating scanning, animals
were placed on a heating pad at 37uC to minimize variations in
temperature. Calculated perfusion is expressed as the ratio of
ischemic to non-ischemic hind limb perfusion.
Histology
Capillaries were scored in 8 mm frozen sections of the adductor
muscles by staining for CD31 (PE-labeled; BD Biosciences).
Images were obtained by confocal microscopy (LSM 510 Meta,
Zeiss, Germany).
Statistical analysis
Results are expressed as mean6SEM. Overall comparison of
the treatment groups was performed with the Kruskal-Wallis test
followed by post-hoc pairwise comparison using the Mann-
Whitney test. P values,0.05 were considered statistically signif-
icant. Analyses were performed with SPSS 15.0 (SPSS Inc.).
Acknowledgments
We are indebted to Christiane Mildner-Rihm, Tino Ro ¨xe, Ariane Fischer,
Marion Muhly-Reinholz, Barbara Birk, and Jaimy Saif for their excellent
assistance.
Author Contributions
Conceived and designed the experiments: AA CH SF MEM RF SD.
Performed the experiments: AA CH SF RF. Analyzed the data: AA CH SF
RF SD. Contributed reagents/materials/analysis tools: SF FH MEM RF.
Wrote the paper: AA CH RF SD. Made critical revision of the drafted
manuscript for important intellectual content: FH MEM.
References
1. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, et al. (1998) Nitric
oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin
Invest 101: 2567–2578.
2. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, et al. (2003)
Essential role of endothelial nitric oxide synthase for mobilization of stem and
progenitor cells. Nat Med 9: 1370–1376.
cGKI for Neovascularization
PLoS ONE | www.plosone.org 6 March 2009 | Volume 4 | Issue 3 | e48793. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other
disease. Nat Med 1: 27–31.
4. Risau W (1997) Mechanisms of angiogenesis. Nature 386: 671–674.
5. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, et al. (1999) Ischemia-
and cytokine-induced mobilization of bone marrow-derived endothelial
progenitor cells for neovascularization. Nat Med 5: 434–438.
6. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, et al. (1998) Evidence for
circulating bone marrow-derived endothelial cells. Blood 92: 362–367.
7. Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, et al. (2003)
Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of
bone marrow-derived endothelial progenitor cells contributes to reendothelia-
lization after arterial injury. Circulation 108: 3115–3121.
8. Laufs U, Werner N, Link A, Endres M, Wassmann S, et al. (2004) Physical
training increases endothelial progenitor cells, inhibits neointima formation, and
enhances angiogenesis. Circulation 109: 220–226.
9. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, et al.
(2004) Statin-induced improvement of endothelial progenitor cell mobilization,
myocardial neovascularization, left ventricular function, and survival after
experimental myocardial infarction requires endothelial nitric oxide synthase.
Circulation 110: 1933–1939.
10. Santhanam AV, d’Uscio LV, Peterson TE, Katusic ZS (2008) Activation of
endothelial nitric oxide synthase is critical for erythropoietin-induced mobiliza-
tion of progenitor cells. Peptides 29: 1451–1455.
11. Hornig B, Arakawa N, Kohler C, Drexler H (1998) Vitamin C improves
endothelial function of conduit arteries in patients with chronic heart failure.
Circulation 97: 363–368.
12. Thum T, Fraccarollo D, Schultheiss M, Froese S, Galuppo P, et al. (2007)
Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell
mobilization and function in diabetes. Diabetes 56: 666–674.
13. Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, et al. (2007) Diabetic
impairments in NO-mediated endothelial progenitor cell mobilization and
homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 117:
1249–1259.
14. Heeschen C, Lehmann R, Honold J, Assmus B, Aicher A, et al. (2004)
Profoundly reduced neovascularization capacity of bone marrow mononuclear
cells derived from patients with chronic ischemic heart disease. Circulation 109:
1615–1622.
15. Sasaki K, Heeschen C, Aicher A, Ziebart T, Honold J, et al. (2006) Ex vivo
pretreatment of bone marrow mononuclear cells with endothelial NO synthase
enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl
Acad Sci U S A 103: 14537–14541.
16. Segal MS, Shah R, Afzal A, Perrault CM, Chang K, et al. (2006) Nitric oxide
cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory
defect associated with diabetes. Diabetes 55: 102–109.
17. Vaandrager AB, de Jonge HR (1996) Signalling by cGMP-dependent protein
kinases. Mol Cell Biochem 157: 23–30.
18. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F (2003) Cyclic GMP-
dependent protein kinases and the cardiovascular system: insights from
genetically modified mice. Circ Res 93: 907–916.
19. Hofmann F, Feil R, Kleppisch T, Schlossmann J (2006) Function of cGMP-
dependent protein kinases as revealed by gene deletion. Physiol Rev 86: 1–23.
20. Draijer R, Vaandrager AB, Nolte C, de Jonge HR, Walter U, et al. (1995)
Expression of cGMP-dependent protein kinase I and phosphorylation of its
substrate, vasodilator-stimulated phosphoprotein, in human endothelial cells of
different origin. Circ Res 77: 897–905.
21. Michael SK, Surks HK, Wang Y, Zhu Y, Blanton R, et al. (2008) High blood
pressure arising from a defect in vascular function. Proc Natl Acad Sci U S A
105: 6702–6707.
22. Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, et al. (1998) Defective smooth
muscle regulation in cGMP kinase I-deficient mice. Embo J 17: 3045–3051.
23. Massberg S, Sausbier M, Klatt P, Bauer M, Pfeifer A, et al. (1999) Increased
adhesion and aggregation of platelets lacking cyclic guanosine 39,59-monophos-
phate kinase I. J Exp Med 189: 1255–1264.
24. Li Z, Xi X, Gu M, Feil R, Ye RD, et al. (2003) A Stimulatory Role for cGMP-
Dependent Protein Kinase in Platelet Activation. Cell 112: 77–86.
25. Foller M, Feil S, Ghoreschi K, Koka S, Gerling A, et al. (2008) Anemia and
splenomegaly in cGKI-deficient mice. Proc Natl Acad Sci U S A 105:
6771–6776.
26. Zhang R, Wang L, Zhang L, Chen J, Zhu Z, et al. (2003) Nitric Oxide Enhances
Angiogenesis via the Synthesis of Vascular Endothelial Growth Factor and
cGMP After Stroke in the Rat. Circ Res 92: 308–313.
27. Pyriochou A, Zhou Z, Koika V, Petrou C, Cordopatis P, et al. (2007) The
phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein
kinase G/MAPK pathway. J Cell Physiol 211: 197–204.
28. Senthilkumar A, Smith RD, Khitha J, Arora N, Veerareddy S, et al. (2007)
Sildenafil promotes ischemia-induced angiogenesis through a PKG-dependent
pathway. Arterioscler Thromb Vasc Biol 27: 1947–1954.
29. Yamahara K, Itoh H, Chun TH, Ogawa Y, Yamashita J, et al. (2003)
Significance and therapeutic potential of the natriuretic peptides/cGMP/
cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl
Acad Sci U S A 100: 3404–3409.
30. Oshita AK, Rothstein G, Lonngi G (1977) cGMP stimulation of stem cell
proliferation. Blood 49: 585–591.
31. Chan SL, Fiscus RR (2003) Guanylyl cyclase inhibitors NS2028 and ODQ and
protein kinase G (PKG) inhibitor KT5823 trigger apoptotic DNA fragmentation
in immortalized uterine epithelial cells: anti-apoptotic effects of basal cGMP/
PKG. Mol Hum Reprod 9: 775–783.
32. Wolfsgruber W, Feil S, Brummer S, Kuppinger O, Hofmann F, et al. (2003) A
proatherogenic role for cGMP-dependent protein kinase in vascular smooth
muscle cells. Proc Natl Acad Sci U S A 100: 13519–13524.
33. Feil R, Feil S, Hofmann F (2005) A heretical view on the role of NO and cGMP
in vascular proliferative diseases. Trends Mol Med 11: 71–75.
34. Fiedler B, Feil R, Hofmann F, Willenbockel C, Drexler H, et al. (2006) cGMP-
dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein
kinase apoptosis signaling in cardiac myocytes. J Biol Chem 281: 32831–32840.
35. Surks HK, Mochizuki N, Kasai Y, Georgescu SP, Tang KM, et al. (1999)
Regulation of myosin phosphatase by a specific interaction with cGMP-
dependent protein kinase Ialpha. Science 286: 1583–1587.
36. Diller GP, van Eijl S, Okonko DO, Howard LS, Ali O, et al. (2008) Circulating
endothelial progenitor cells in patients with Eisenmenger syndrome and
idiopathic pulmonary arterial hypertension. Circulation 117: 3020–3030.
37. Wegener JW, Nawrath H, Wolfsgruber W, Kuhbandner S, Werner C, et al.
(2002) cGMP-dependent protein kinase I mediates the negative inotropic effect
of cGMP in the murine myocardium. Circ Res 90: 18–20.
38. Walter DH, Rochwalsky U, Reinhold J, Seeger F, Aicher A, et al. (2007)
Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by
activation of the CXCR4-dependent signaling pathway via the S1P3 receptor.
Arterioscler Thromb Vasc Biol 27: 275–282.
39. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, et al. (2004)
Identification of a novel hierarchy of endothelial progenitor cells using human
peripheral and umbilical cord blood. Blood 104: 2752–2760.
40. Feil S, Zimmermann P, Knorn A, Brummer S, Schlossmann J, et al. (2005)
Distribution of cGMP-dependent protein kinase type I and its isoforms in the
mouse brain and retina. Neuroscience 135: 863–868.
41. Fajardo LF, Kowalski J, Kwan HH, Prionas SD, Allison AC (1988) The disc
angiogenesis system. Lab Invest 58: 718–724.
42. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, et al. (2001) Nicotine stimulates
angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 7:
833–839.
43. Springer ML, Ip TK, Blau HM (2000) Angiogenesis monitored by perfusion
with a space-filling microbead suspension. Mol Ther 1: 82–87.
cGKI for Neovascularization
PLoS ONE | www.plosone.org 7 March 2009 | Volume 4 | Issue 3 | e4879